Evidence map›Paper›PMID 33532764›Full record

ArticlebioRxiv : the preprint server for biology2021

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.

Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, James Theiler, Hyejin Yoon, Dapeng Li, Barton F Haynes, Kevin O Sanders and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 78 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Xiaoying ShenDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Haili TangDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Charlene McDanalDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Kshitij WaghTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
Will FischerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
James TheilerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
Hyejin YoonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
Dapeng LiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kevin O SandersDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Sandrasegaram GnanakaranTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
Nick HengartnerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
Rolando PajonModerna Inc., Cambridge, MA, USA.
Gale SmithNovavax, Inc., Gaithersburg, MD, USA.
Filip DubovskyNovavax, Inc., Gaithersburg, MD, USA.
Gregory M GlennNovavax, Inc., Gaithersburg, MD, USA.
Bette KorberTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA.
David C MontefioriDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Duke University · USLos Alamos National Laboratory · USNovavax (United States) · USModerna Therapeutics (United States) · US

Funding

Project 2 - GMP Manufacturing of mRNA ImmunogensU19AI142596 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2024
$19.0M
NIAID NIH HHS U19 AI142596
6 · The paper itself

Abstract

The SARS-CoV-2 Spike glycoprotein mediates virus entry and is a major target for neutralizing antibodies. All current vaccines are based on the ancestral Spike with the goal of generating a protective neutralizing antibody response. Several novel SARS-CoV-2 variants with multiple Spike mutations have emerged, and their rapid spread and potential for immune escape have raised concerns. One of these variants, first identified in the United Kingdom, B.1.1.7 (also called VUI202012/01), contains eight Spike mutations with potential to impact antibody therapy, vaccine efficacy and risk of reinfection. Here we employed a lentivirus-based pseudovirus assay to show that variant B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels (~2-fold), by serum samples from convalescent individuals and recipients of two different vaccines based on ancestral Spike: mRNA-1273 (Moderna), and protein nanoparticle NVX-CoV2373 (Novavax). Some monoclonal antibodies to the receptor binding domain (RBD) of Spike were less effective against the variant while others were largely unaffected. These findings indicate that B.1.1.7 is not a neutralization escape variant that would be a major concern for current vaccines, or for an increased risk of reinfection.

Identifiers

PMID33532764
PMCPMC7852228
OpenAlexW3123644181

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.